Manufacturers express no bias against developing a new drug for mental health indications in comparison with physical health indications.
- However, because many persons with mental illness have public health insurance, patient recruitment and retention in trials can be a greater challenge for behavioral health than for physical health drugs.
The MCOs and PBMs interviewed reported that traditional clinical trials are of relatively short duration and measure outcomes using instruments not readily translatable into regular clinical practice, such as standardized psychiatric rating scales.
Manufacturers devote considerable effort to marketing psychotherapeutics to physicians and patients, although tactics vary. The extent to which marketing efforts affect sales success has not been quantified.
Although it is generally assumed that manufacturer contracts and rebates may affect drug utilization, no data exists to support this idea, largely because such data are considered trade secrets.